145 related articles for article (PubMed ID: 23084250)
1. Influence of bioluminescence imaging dynamics by D-luciferin uptake and efflux mechanisms.
Zhang Y; Pullambhatla M; Laterra J; Pomper MG
Mol Imaging; 2012; 11(6):499-506. PubMed ID: 23084250
[TBL] [Abstract][Full Text] [Related]
2. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging.
Zhang Y; Bressler JP; Neal J; Lal B; Bhang HE; Laterra J; Pomper MG
Cancer Res; 2007 Oct; 67(19):9389-97. PubMed ID: 17909048
[TBL] [Abstract][Full Text] [Related]
3. Uptake kinetics and biodistribution of 14C-D-luciferin--a radiolabeled substrate for the firefly luciferase catalyzed bioluminescence reaction: impact on bioluminescence based reporter gene imaging.
Berger F; Paulmurugan R; Bhaumik S; Gambhir SS
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2275-85. PubMed ID: 18661130
[TBL] [Abstract][Full Text] [Related]
4. ATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imaging.
Huang R; Vider J; Serganova I; Blasberg RG
Mol Imaging; 2011 Jun; 10(3):215-26. PubMed ID: 21496450
[TBL] [Abstract][Full Text] [Related]
5. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism.
Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y
Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644
[TBL] [Abstract][Full Text] [Related]
6. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
Zhang Y; Byun Y; Ren YR; Liu JO; Laterra J; Pomper MG
Cancer Res; 2009 Jul; 69(14):5867-75. PubMed ID: 19567678
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells.
Sun Y; Gu M; Zhu L; Liu J; Xiong Y; Wei Y; Li F
Anticancer Drugs; 2016 Mar; 27(3):183-91. PubMed ID: 26556627
[TBL] [Abstract][Full Text] [Related]
8. Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor.
Kim M; Gupta SK; Zhang W; Talele S; Mohammad AS; Laramy J; Mladek AC; Zhang S; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2022 Mar; 50(3):277-286. PubMed ID: 34887255
[TBL] [Abstract][Full Text] [Related]
9. In Vivo Bioluminescent Imaging of ATP-Binding Cassette Transporter-Mediated Efflux at the Blood-Brain Barrier.
Bakhsheshian J; Wei BR; Hall MD; Simpson RM; Gottesman MM
Methods Mol Biol; 2016; 1461():227-39. PubMed ID: 27424909
[TBL] [Abstract][Full Text] [Related]
10. Evaluating Brightness and Spectral Properties of Click Beetle and Firefly Luciferases Using Luciferin Analogues: Identification of Preferred Pairings of Luciferase and Substrate for In Vivo Bioluminescence Imaging.
Zambito G; Gaspar N; Ridwan Y; Hall MP; Shi C; Kirkland TA; Encell LP; Löwik C; Mezzanotte L
Mol Imaging Biol; 2020 Dec; 22(6):1523-1531. PubMed ID: 32926287
[TBL] [Abstract][Full Text] [Related]
11. Organic anion transporter 1 (OAT1/SLC22A6) enhances bioluminescence based on d-luciferin-luciferase reaction in living cells by facilitating the intracellular accumulation of d-luciferin.
Furuya T; Takehara I; Shimura A; Kishimoto H; Yasujima T; Ohta K; Shirasaka Y; Yuasa H; Inoue K
Biochem Biophys Res Commun; 2018 Jan; 495(3):2152-2157. PubMed ID: 29273507
[TBL] [Abstract][Full Text] [Related]
12. Comparison of subcutaneous and intraperitoneal injection of D-luciferin for in vivo bioluminescence imaging.
Inoue Y; Kiryu S; Izawa K; Watanabe M; Tojo A; Ohtomo K
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):771-9. PubMed ID: 19096841
[TBL] [Abstract][Full Text] [Related]
13. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
[TBL] [Abstract][Full Text] [Related]
14. The Drug Excipient Cyclodextrin Interacts With d-Luciferin and Interferes With Bioluminescence Imaging.
Kumar JS; Miller Jenkins LM; Gottesman MM; Hall MD
Mol Imaging; 2016; 15():. PubMed ID: 27030398
[TBL] [Abstract][Full Text] [Related]
15. Oatp1 enhances bioluminescence by acting as a plasma membrane transporter for D-luciferin.
Patrick PS; Lyons SK; Rodrigues TB; Brindle KM
Mol Imaging Biol; 2014 Oct; 16(5):626-34. PubMed ID: 24798747
[TBL] [Abstract][Full Text] [Related]
16. Recent achievements of bioluminescence imaging based on firefly luciferin-luciferase system.
Li S; Ruan Z; Zhang H; Xu H
Eur J Med Chem; 2021 Feb; 211():113111. PubMed ID: 33360804
[TBL] [Abstract][Full Text] [Related]
17. How to Select Firefly Luciferin Analogues for In Vivo Imaging.
Saito-Moriya R; Nakayama J; Kamiya G; Kitada N; Obata R; Maki SA; Aoyama H
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673331
[TBL] [Abstract][Full Text] [Related]
18. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.
Scharenberg CW; Harkey MA; Torok-Storb B
Blood; 2002 Jan; 99(2):507-12. PubMed ID: 11781231
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
[TBL] [Abstract][Full Text] [Related]
20. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
